Accuray Inc.

Company Snapshot

Founded: 1990
Entity Type: Public
Employees: 987
Region: Europe India Middle East and Africa (EIMEA)
Revenue: $446.6 Millions
Revenue Year: 2023
Headquarter: Wisconsin, U.S.
Key Geographics: Europe India Middle East and Africa (EIMEA), Americas, China, Japan, Asia-Pacific (excluding China)
Corporate Address: 1240 Deming Way Madison, Wisconsin 53717-1954 U.S. Tel. +1-608-824-2800 www.accuray.com

Company Overview

Accuray Inc. is a leading manufacturer of radiation oncology systems. The company offers hardware, software and services for radiation therapy and radiosurgery treatments. The company’s CyberKnife and TomoTherapy platforms, including the Radixact System, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART).

Accuray has more than 1,000 radiation and radiosurgery systems installed worldwide.   It has manufacturing facilities in the U.S. and China.

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Accuray Inc. In Reports

Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets

BCC Research Market Analyst says global market for global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end...

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

BCC Research Market Analyst says global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a CAGR of 8.3% from 2023 through 2028.

Ablation Devices: Technologies and Global Markets

BCC Research Market Report says global market for ablation devices is estimated to increase from $6.5 bln in 2022 to reach $11.3 bln by 2027, at a (CAGR) of 11.8%.

Company's Business Segments

  • Products : CyberKnife, Radixact, TomoTherapy, Accuray Precision Treatment Planning, iDMS Data Management, Veterinary Oncology
  • Services : Radiotherapy Support Program, Others

Applications/End User Industries

  • Oncology
  • Hospitals
  • Academic Medical Centers
  • Clinics
  • Research Institutions